<DOC>
	<DOC>NCT02338323</DOC>
	<brief_summary>The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function, and which one could be better.</brief_summary>
	<brief_title>Compare the Renal Protective Effects of Febuxostat and Benzbromarone</brief_title>
	<detailed_description>Chronic kidney disease patients with hyperuricemia and glomerular filtration rate (GFR) 20-50 ml/min were treated by febuxostat or benzbromarone. Follow up the changes of serum uric acid, serum creatinine and GFR levels. Compare the effects on renal function of these two drugs.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<mesh_term>Benzbromarone</mesh_term>
	<criteria>Chronic kidney disease patients with glomerular filtration rate (GFR,2050ml/min) who match one of the following criteria: 1. Gout 2. Hyperuricemia patients without gout but have cardiovascular risk and serum uric acid &gt; 480umol/L 3. Hyperuricemia patients without gout but with serum uric acid &gt; 540umol/L 1. GFR&lt;20ml/min or GFR &gt;50ml/min 2. Liver dysfunction (Aspartate transaminase or/and alanine aminotransferase exceed 2 times of normal range) 3. Urinary tract obstruction 4. unstable angina, heart failure (stage IIIIV, NYHA), new stroke, need diuretics for longterm treatment 5. Severe lung diseases or cancers 6. Pregnant woman or woman who prepare to be pregnant，nursing mothers 7. unable to sign informed consent form，or disagree with followingup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hyperuricemia</keyword>
	<keyword>Renal Function</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Febuxostat</keyword>
	<keyword>Benzbromarone</keyword>
</DOC>